Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
- Status
- COMPLETED
- Phase
- PHASE2
Short Course Daratumumab in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
- Status
- COMPLETED
- Phase
- N/A
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
- Status
- COMPLETED
- Phase
- PHASE4
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Status
- COMPLETED
- Phase
- PHASE2
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
- Status
- TERMINATED
- Phase
- PHASE2
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
- Status
- TERMINATED
- Phase
- PHASE2
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
- Status
- WITHDRAWN
- Phase
- PHASE1
Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2